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BACKGROUND
In the United States, mifepristone is available for medical abortion (for use with 
misoprostol) only with Risk Evaluation and Mitigation Strategy (REMS) restrictions, 
despite an absence of evidence to support such restrictions. Mifepristone has been 
available in Canada with a normal prescription since November 2017.
METHODS
Using population-based administrative data from Ontario, Canada, we examined 
abortion use, safety, and effectiveness using an interrupted time-series analysis 
comparing trends in incidence before mifepristone was available (January 2012 
through December 2016) with trends after its availability without restrictions 
(November 7, 2017, through March 15, 2020).
RESULTS
A total of 195,183 abortions were performed before mifepristone was available and 
84,032 after its availability without restrictions. After the availability of mifepris-
tone with a normal prescription, the abortion rate continued to decline, although 
more slowly than was expected on the basis of trends before mifepristone had 
been available (adjusted risk difference in time-series analysis, 1.2 per 1000 female 
residents between 15 and 49 years of age; 95% confidence interval [CI], 1.1 to 1.4), 
whereas the percentage of abortions provided as medical procedures increased 
from 2.2% to 31.4% (adjusted risk difference, 28.8 percentage points; 95% CI, 28.0 
to 29.7). There were no material changes between the period before mifepristone 
was available and the nonrestricted period in the incidence of severe adverse events 
(0.03% vs. 0.04%; adjusted risk difference, 0.01 percentage points; 95% CI, −0.06 
to 0.03), complications (0.74% vs. 0.69%; adjusted risk difference, 0.06 percentage 
points; 95% CI, −0.07 to 0.18), or ectopic pregnancy detected after abortion (0.15% 
vs. 0.22%; adjusted risk difference, −0.03 percentage points; 95% CI, −0.19 to 
0.09). There was a small increase in ongoing intrauterine pregnancy continuing to 
delivery (adjusted risk difference, 0.08%; 95% CI, 0.04 to 0.10).
CONCLUSIONS
After mifepristone became available as a normal prescription, the abortion rate 
remained relatively stable, the proportion of abortions provided by medication 
increased rapidly, and adverse events and complications remained stable, as com-
pared with the period when mifepristone was unavailable. (Funded by the Cana-
dian Institutes of Health Research and the Women’s Health Research Institute.)
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Access to safe abortion is a human right and a key component of reproduc-tive health, yet inadequate access remains 
a global concern.1 A medical abortion regimen 
of mifepristone and misoprostol has been shown 
to be safe.2-4 Mifepristone is approved for use in 
the United States with Risk Evaluation and Miti-
gation Strategy (REMS) restrictions5 (including 
mandatory prescriber certification, observed dos-
ing, dispensing by the prescriber or medical fa-
cility with the exclusion of pharmacies, and sub-
mission of a prespecified patient consent form) 
and elsewhere with similar restricted approvals.6,7 
Professional organizations have called for the 
removal of REMS restrictions because they im-
pede access to abortion services without improv-
ing safety.8 However, high-quality data with re-
spect to abortion safety and effectiveness when 
mifepristone is available without REMS-like re-
strictions are lacking.9
Mifepristone was first marketed in Canada in 
January 2017 as a 200-mg tablet combined with 
800 μg of misoprostol.10 Approval came more 
than 15 years after approval in the United States 
and more than 25 years after similar rulings in 
France, Sweden, and the United Kingdom.11 Ini-
tially, regulatory restrictions in Canada were simi-
lar to REMS restrictions.12 By November 7, 2017, 
Canadian regulators had removed these restric-
tions so that mifepristone could be prescribed 
and dispensed as a normal prescription medica-
tion and had expanded approved use from 49 to 
63 days after the patient’s last menstrual peri-
od.13 This action resulted in a globally unprece-
dented practice of permitting any physician or 
nurse practitioner to prescribe, any pharmacist 
to dispense, and patients to independently ad-
minister mifepristone when, where, and if they 
chose.14 Before 2017, medically induced abortions 
made up only 4% of all abortions in Canada and 
used off-label regimens of misoprostol with or 
without methotrexate. These regimens have re-
duced effectiveness (84 to 97%) and a high risk 
of teratogenicity if the abortion fails.4,15
We compared abortion use, safety, and effec-
tiveness during the period after mifepristone had 
become available without REMS-like restrictions 
with the period before mifepristone had been 
available in Ontario, Canada (representing nearly 
40% of the Canadian population).
Me thods
Data Set
In Canada, universal single-payer health care — 
including coverage for abortion services and man-
agement of its complications — is provided by 
each province or territory. We used linked ad-
ministrative health data16 to create a population-
based cohort of all female Ontario residents be-
tween the ages of 12 and 49 years who had 
received abortion services from January 1, 2012, 
to March 15, 2020. We linked records from prac-
titioner visits, all hospital visits, and outpatient 
prescriptions using a secure data platform at 
ICES (formerly known as the Institute for Clinical 
Evaluative Sciences) at McMaster University.16,17 
We excluded events that had occurred within 6 
weeks before or after a missed abortion (preg-
nancy loss without expulsion) or spontaneous 
abortion (pregnancy loss with expulsion) and 
those occurring within 6 weeks after delivery at 
25 weeks or more of gestation to avoid including 
procedures that could have been misclassified as 
abortions. Details regarding the data set are 
provided in Figure S1 and Table S1 in the Sup-
plementary Appendix, available with the full text 
of this article at NEJM.org. Ethics approval for 
the study was granted by the University of Brit-
ish Columbia.
Exposure and Outcomes
The exposure we examined was the regulatory 
change that made mifepristone available as a nor-
mal prescription. Outcomes included measures 
of abortion use, safety, and effectiveness.
We evaluated outcomes regarding abortion use 
that included the abortion rate, which was calcu-
lated according to the international standard as 
the annual number of abortions among female 
residents between 15 and 49 years of age per 
1000 female residents in that age group,18 the 
percentage of all abortions that were medically 
induced, and the percentage of all abortions that 
were provided at 14 weeks or more of gestation 
(second-trimester abortion). (In the calculation of 
the abortion rate, the lower age for female resi-
dents was 15 years, as compared with a lower age 
of 12 years that was used for all other calculations 
in our study cohort.) Abortion safety outcomes 
within 6 weeks after abortion were severe adverse 
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events, including any blood transfusion, abdomi-
nal surgery (laparotomy, laparoscopy, or hyster-
ectomy), admission to an intensive care unit, or 
sepsis that occurred during a hospitalization 
associated with an abortion-complication code. 
Complications of abortion included genital tract or 
pelvic infection, hemorrhage (delayed or exces-
sive bleeding that complicated complete or in-
complete abortion), embolism, shock, renal fail-
ure, damage to pelvic organs or tissues (including 
uterine perforation), venous complications, and 
other or unspecified complications. Outcomes re-
garding abortion effectiveness were the incidence 
of subsequent uterine evacuation (aspiration af-
ter medical abortion, reaspiration after surgical 
abortion, or subsequent abortion procedure), on-
going intrauterine pregnancy continuing until 
delivery, and ectopic pregnancy diagnosed within 
6 weeks after the abortion date. Detailed out-
come definitions are provided in Table S1.
Statistical Analysis
We tabulated the incidence of each outcome ac-
cording to the mifepristone regulatory period. 
We then conducted interrupted time-series anal-
ysis using segmented generalized mixed-effects 
regression to compare the expected incidence 
and trend for each outcome based on the period 
before mifepristone had become available with 
the observed level and trend after the availability 
of mifepristone with a normal prescription. We 
used log binomial regression to model incidence 
outcomes and Poisson regression with popula-
tion offset to calculate the abortion rate; models 
were adjusted for outcome trends before the ap-
proval of mifepristone and accounted for auto-
correlation and correlated residuals (File 1 in the 
Supplementary Appendix).19,20 We used 6-month 
moving averages to smooth the resulting esti-
mates. We examined outcomes from January 1, 
2017, through November 6, 2017, descriptively 
but excluded this period from our models be-
cause it included rapid, incremental regulatory 
changes.13
We graphed the observed and expected month-
ly outcome incidence (quarterly for outcomes with 
<6 events in any month) following best practic-
es.21 We estimated risk differences and risk ra-
tios for each outcome by comparing the observed 
with expected values for September 2019, a time 
point selected a priori to balance model stability 
(greatest in the middle of the study period) and 
integration of mifepristone into practice (great-
est at the end of the study period). We used boot-
strapping with 200 samples drawn with replace-
ment to estimate 95% confidence intervals22 
without adjustment for multiple comparisons. All 
analyses were conducted with the use of SAS soft-
ware, version 7.51, and R software (code in File 2 
in the Supplementary Appendix).
To examine the robustness of our findings to 
modeling specification, we conducted sensitiv-
ity analyses using segmented generalized least-
squares regression, with autocorrelation terms 
selected on the basis of the Durbin–Watson 
test23-25 and visual examination of autocorrelation 
function and partial autocorrelation function re-
siduals.25 We conducted subgroup analyses that 
were restricted to first-trimester abortions and 
then further restricted to first-trimester medical 
abortions.
R esult s
Characteristics of the Study Population
Of the 314,859 induced abortions in Ontario, 
Canada, from January 1, 2012, through March 15, 
2020, the majority (89.3%) were surgical (with 
94.6% performed by means of suction aspiration), 
approximately 10% were medical abortions, and 
less than 0.1% were unclassified. Table 1 shows 
cohort characteristics according to the regula-
tory period for mifepristone.
Descriptive Analyses of Abortion Outcomes
The abortion rate per 1000 female residents of re-
productive age and the incidence of all other out-
comes are presented descriptively according to the 
regulatory period in Table 2. (Components of the 
composite outcomes are shown in Table S2.) 
The abortion rate decreased from 11.9 abortions 
per 1000 female residents between the ages of 
15 and 49 years of age before mifepristone had 
become available to 11.3 per 1000 female resi-
dents after mifepristone had become available with 
a normal prescription. The percentage of all abor-
tions that were provided medically increased from 
2.2% before mifepristone had become available to 
8.3% while mifepristone was restricted and then 
to 31.4% after mifepristone had become avail-
able with a normal prescription. The rate of 
second-trimester abortions declined from 5.5% 
of all abortions to 5.1% after the availability of 
mifepristone with a normal prescription.
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Abortion safety outcomes remained stable dur-
ing the period before mifepristone had become 
available and during the period after its availabil-
ity with a normal prescription (severe adverse 
events, 0.03% and 0.04%, respectively; and abor-
tion complications, 0.67% and 0.74%, respective-
ly). Subsequent uterine evacuation increased from 
1.0% to 2.2%, and ongoing intrauterine pregnancy 
continuing until delivery increased from 0.03% to 
0.08%. Ectopic pregnancy that was detected af-
ter abortion increased from 0.15% to 0.22%.
Time-Series Analyses of Abortion Outcomes
Interrupted time-series graphs of abortion-use 
outcomes are presented in Figure 1, abortion 
safety outcomes in Figure 2, and abortion-effec-
tiveness outcomes in Figure 3. Adjusted risk 
differences and risk ratios from these models 
comparing the period before mifepristone had 
become available with the nonrestricted period 
are presented in Table 2.
During the study period, the abortion rate 
continued an absolute decline, although as com-
pared with the trend before the approval of 
mifepristone, we noted an increase of 1.2 abor-
tions per 1000 female residents (95% confidence 
interval [CI], 1.1 to 1.4) over the predicted rate. 
The proportion of all abortions that were medi-
cal increased by an adjusted risk difference of 
28.8 percentage points (95% CI, 28.0 to 29.7). 














January 1, 2017– 
November 6, 2017
November 7, 2017– 
March 15, 2020
number of patients (percent)
Age — yr*
<20 20,034 (10.3) 2,969 (8.3) 6,643 (7.9)
20–24 54,346 (27.8) 9,208 (25.8) 20,247 (24.1)
25–29 47,598 (24.4) 8,909 (25.0) 21,717 (25.8)
30–34 36,640 (18.8) 7,369 (20.7) 17,838 (21.2)
≥35 36,565 (18.7) 7,189 (20.2) 17,587 (20.9)
Nulliparous 104,824 (53.7) 19,030 (53.4) 45,902 (54.6)
Neighborhood income†
Lowest quintile 55,076 (28.2) 9,737 (27.3) 22,360 (26.6)
Highest quintile 24,852 (12.7) 4,603 (12.9) 11,075 (13.2)
Neighborhood ethnic concentra-
tion‡
Highest quintile 82,143 (42.1) 14,627 (41.0) 33,600 (40.0)
Lowest quintile 19,424 (10.0) 3,552 (10.0) 8,451 (10.1)
Rural residence§ 11,709 (6.0) 2,174 (6.1) 5,195 (6.2)
*  Trends regarding the patient’s age at which abortion was performed in Ontario continued a historic gradual and steady 
increase over the study period, which was consistent with an increase in age in the population-based trends during this 
period.
†  The neighborhood income quintile was drawn from the Registered Persons Database file from the Institute for Clinical 
Evaluative Sciences and was defined on the basis of the Nearest Census-Based Neighborhood Income Quintile from 
Census Canada.
‡  The neighborhood ethnic concentration, which is part of the Ontario Marginalization Index,26 refers to high area-level 
percentages of recent immigrants and persons belonging to a “visible minority” group, which was defined by Statistics 
Canada as “persons, other than aboriginal peoples, who are non-Caucasian in race or non-white in color.” The highest 
concentration of such residents is the top quintile, and the lowest concentration is the lowest quintile.
§  Rural residence is defined as all territory lying outside population centers.
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The rate of second-trimester abortions showed a 
stable, continuous decline (adjusted risk differ-
ence, −0.22 percentage points; 95% CI, −0.63 to 
0.19). Abortion safety outcomes were materially 
stable, with an adjusted risk difference of 0.01 
percentage points (95% CI, −0.06 to 0.03) for 
severe adverse events and 0.06 percentage points 
(95% CI, −0.07 to 0.18) for complications. The 
rate of subsequent uterine evacuation increased 
modestly, with an adjusted risk difference of 1.1 
percentage points (95% CI, 0.91 to 1.3), and the 
rate of ongoing intrauterine pregnancy that con-
tinued until delivery increased by 0.08 percent-
age points (95% CI, 0.04 to 0.10). The rate of 
ectopic pregnancy that was detected after abor-
tion was materially stable, with an adjusted risk 
difference of −0.03 percentage points (95% CI, 
−0.19 to 0.09).
Interrupted time-series graphs from general-
ized least-squares regression with the use of 
aggregated monthly data showed the robustness 
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Figure 1. Changes in the Percentages of Medical and 
Second-Trimester Abortions among All Abortions and 
in Abortion Rates.
Shown are the results of interrupted time-series analy-
ses of the level and trend of abortion outcomes in 
Ontario, Canada, among all surgical and medical 
abortions that were provided before the introduction 
of mifepristone in the province (2012 through 2016), 
after the introduction but with Risk Evaluation and 
Mitigation Strategy (REMS)–like restrictions (January 1, 
2017, through November 6, 2017), and after a regula-
tory change to remove restrictions, which made mife-
pristone available by normal prescription (November 
7, 2017, through March 15, 2020). Panel A shows the 
percentage of all abortions that were performed medi-
cally at any gestational age. Panel B shows the annual 
abortion rate among female residents between the 
ages of 15 and 49 years per 1000 female residents in 
the same age group in the population. Panel C shows 
the percentage of second-trimester abortions (≥14 weeks 
of gestation) among all abortions. In Panels B and C, 
the insets show the same data on an expanded y axis; 
shading indicates 95% confidence intervals. The ex-
pected outcomes if mifepristone had not been avail-
able were estimated from segmented mixed-effects 
models (log binomial regression in Panels A and C 
and Poisson regression with population offset in Panel B) 
and smoothed with the use of a 6-month moving-aver-
age function.
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S2, S3, and S4). Changes in outcome incidences 
and trends after mifepristone availability with a 
normal prescription were consistent for all out-
comes except for the percentage of second-tri-
mester abortions, for which aggregated models 
indicated a slight reduction (−0.92 percentage 
points; 95% CI, −1.40 to −0.48).
 Outcomes after First-Trimester Abortion
Outcome incidences among all first-trimester 
abortions are presented in Tables S3 and S4 and 
Figures S5, S6, and S7; outcomes among first-
trimester medical abortions are provided in Ta-
bles S5 and S6. The percentage of first-trimester 
abortions that were performed medically increased 
from 1.6% before mifepristone was available to 
32.4% after mifepristone was available without 
restrictions. Severe adverse events were rare among 
first-trimester medical abortions (<6 events per 
25,744 abortions [too infrequent to report exact 
incidence]), the incidence of abortion complica-
tions was 0.76%, and the incidence of subsequent 
uterine evacuation was 4.5%. Similarly, ongoing 
intrauterine pregnancy was uncommon, with 
0.13% continuing to delivery. Ectopic pregnancy 
detected after abortion that occurred with any 
severe adverse event was also rare (<6 per 314,859 
abortions).
 Discussion
We comprehensively examined changes in abor-
tion use, safety, and effectiveness during the 
period when mifepristone had become available 
without REMS-like restrictions in a population-
based cohort of abortion service users in On-
tario, Canada. We found that after mifepristone 
had become available with a normal prescription 
dispensed by pharmacists and taken at user dis-
cretion, abortion rates were materially stable, 
medical abortion uptake was rapid, and abor-
tion-related adverse events and ectopic preg-
nancy remained rare, as compared with before 
mifepristone had been available.
The modestly slower decline in the abortion 
rate, relative to the expected decline based on 
the trend before mifepristone had become avail-
able, may be due in part to the provision of abor-
tion earlier in pregnancy. Since 4 to 7% of preg-
nancies per week in the first trimester27 end in 
spontaneous abortion, the availability of abortion 
at earlier gestational ages would increase the abor-
tion rate by enabling termination of pregnancy 
before the occurrence of miscarriage, even in the 
absence of a true increase in demand for abor-
tion. The availability of mifepristone without re-
strictions may have slowed the decline in the abor-
tion rate through improved abortion access, a 
Figure 2. Changes in Abortion Safety Outcomes.
Shown are the results of interrupted time-series analyses of the level and 
trend of abortion safety in Ontario, Canada, among all surgical and medi-
cal abortions provided during the study period. Panel A shows the inci-
dence of severe adverse events, which included any blood transfusion, ab-
dominal surgery (laparotomy, laparoscopy, or hysterectomy), admission to 
an intensive care unit, or sepsis that occurred during a hospitalization as-
sociated with an abortion-complication code. Panel B shows abortion com-
plications, which included genital tract or pelvic infection, hemorrhage, 
embolism, shock, renal failure, damage to pelvic organs or tissues, venous 
complications, and other or unspecified abortion complications. In Panel 
A, the inset shows the same data on an expanded y axis; shading indicates 
95% confidence intervals.
B Abortion Complication
A Severe Adverse Event
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hypothesis that is consistent with findings that 
restrictive policies regarding the prescription of 
mifepristone worsen access to abortion28 and that 
abortion rates increase when access improves.29
Because we did not measure pregnancy intention 
in our study, we cannot differentiate trend chang-
es in unintended pregnancy from changes in the 
fraction of pregnancies that were terminated. 
Our findings indicate that improved abortion ac-
cess was not associated with a material increase 
in the abortion rate.
The uptake of mifepristone for medical abor-
tion under Canada’s unrestricted regulations was 
faster than reported in settings with restrictive 
regulations. Although more than one third of 
abortions in Ontario were medically induced 
2 years after mifepristone had been available as 
a normal prescription, 5.2% of abortions in the 
United States were medically induced 2 years 
after mifepristone availability, with the percent-
age slowly increasing to 39.0% 17 years after avail-
ability.2 Similarly slower uptake has been reported 
in European settings that have mifepristone re-
strictions, even among those where mifepristone 
had been introduced long after best practice 
guidelines had been established.30
Our findings indicate that abortion remained 
safe and ongoing pregnancy remained infre-
quent after unrestricted access to mifepristone. 
Without observed administration, some patients 
with a prescription for mifepristone may have 
never used it.9 However, the infrequent occur-
rence of ongoing intrauterine pregnancy indi-
cates that patients who received mifepristone 
most often correctly used the medication with-
out supervision.31 Our abortion safety and effec-
tiveness findings are consistent with the results 
B Subsequent Delivery
A Subsequent Uterine Evacuation

































































Figure 3. Abortion Effectiveness and Ongoing 
Pregnancy Outcomes.
Shown are the results of interrupted time-series analy-
ses of the level and trend of ongoing pregnancy out-
comes among all surgical and medical abortions 
provided during the study period. These outcomes in-
clude the incidences of uterine evacuation after abor-
tion (Panel A), ongoing intrauterine pregnancy con-
tinuing until delivery (Panel B), and ectopic pregnancy 
detected after abortion (Panel C). Shading indicates 
95% confidence intervals.
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of recent studies examining patient-reported out-
comes during the coronavirus disease 2019 pan-
demic, when REMS-like restrictions were tempo-
rarily removed in some settings.9,32,33 A study 
involving 52,142 patients in the United Kingdom 
showed no material differences in success rates 
or serious adverse events between abortions pro-
vided under REMS-like restrictions and a tele-
medicine-hybrid model with investigations such 
as ultrasonography performed only when indi-
cated.33
The small increase in the incidence of ectopic 
pregnancy that was detected after unrestricted 
access to mifepristone was consistent with the 
increasing trend before the availability of mife-
pristone, which indicated no increase over the 
expected incidence. A 2012 cross-sectional survey 
of abortion providers in the United States and 
Canada showed that more than 90% of providers 
routinely performed ultrasonography before abor-
tion,34 even though the value of such imaging in 
the absence of known ectopic risks or symptoms 
had not been shown.2,35 Ectopic pregnancy is 
more likely to be detected after abortion that is 
provided at earlier stages of gestation before a 
clinical or ultrasonographic diagnosis. Because 
undiagnosed ectopic pregnancy can lead to tubal 
rupture and death,36 identifying ectopic pregnan-
cy before the onset of complications with the use 
of clear clinical protocols2,4 is essential, although 
such procedures do not need to be performed 
before the initiation of medical abortion.33
Our safety and ongoing pregnancy findings 
among first-trimester medical abortions during 
the period after unrestricted access to mifepris-
tone were consistent with reports from other 
settings with restricted access.2,4 In settings with 
REMS-like restrictions, first-trimester medical 
abortions resulted in major adverse events in 0.3 to 
0.5% of women2,4,31 and blood transfusion in 
0.04 to 0.10%.4,31 Among medical abortions per-
formed up to 63 days after the last menstrual 
period, subsequent uterine evacuation occurred 
in 2.0 to 4.8% of patients and ongoing intrauterine 
pregnancy in 0.5 to 2.0%.2,4 In our study among 
first-trimester abortions, severe adverse events 
were too infrequent to report an incidence value, 
0.04% of the patients underwent blood transfu-
sion, 4.5% underwent uterine evacuation, and 
0.13% had an ongoing pregnancy continuing to 
delivery. Although the incidence of uterine evac-
uation was increasing before mifepristone had 
become available, the expected incidence trend 
after the availability of mifepristone leveled off 
because of the more rapid increase in the num-
ber of abortions (the denominator). Because sub-
sequent uterine evacuation is substantially more 
frequent after medical abortion than after surgi-
cal procedures (<3.0%),4,37 a practice shift to more 
medical abortions is expected to increase the in-
cidence of this outcome.
Our study has several potential limitations. 
The fundamental assumption underlying the 
validity of interrupted time-series analysis is that 
outcome trends before the exposure of interest 
would have continued if the exposure had not 
occurred. This assumption does not hold if 
other policy, practice, or contextual changes that 
may have an effect on outcome incidence occur 
concurrent to the exposure of interest.20 How-
ever, this analytic approach is robust with re-
spect to changes in the individual-level charac-
teristics of patients or provider practices that 
accrue gradually over the study period, since such 
changes are accounted for in trend regression 
terms during the period before mifepristone had 
become available. Careful review of policies, aca-
demic literature, practice guidelines, and media 
output that are related to abortion during the study 
period identified no concurrent changes that would 
have invalidated our analytic approach. Practitio-
ner fees, training programs, administrative data 
codes, and cost coverage for the drug were stable 
during the study period. Surveys and interviews 
among practitioners indicate that initial mife-
pristone restrictions were barriers to broad adop-
tion of this practice.13,38 The short period during 
which mifepristone was available in Canada with 
REMS-like restrictions (January 1 to November 6, 
2017) precludes a formal analysis of mifepristone 
availability with restrictions as compared with 
such availability without restrictions. The unre-
stricted availability of mifepristone appears to 
be the fundamental factor associated with chang-
es in our study outcomes.
Our prescription database universally cap-
tured mifepristone prescriptions that were dis-
pensed after August 10, 2017 (when a universal 
no-cost subsidy was introduced) but only cap-
tured mifepristone prescriptions from January to 
August 9, 2017, among patients with income-
based prescription subsidies and those under 25 
years of age. These factors may have contributed 
to an underestimation of early mifepristone up-
n engl j med nejm.org 10
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take. However, this limitation was mitigated by 
our identification of medical abortions using data 
regarding practitioner payments, procedures, and 
prescriptions, along with our exclusion of these 
months from our time-series analysis. Our pop-
ulation-based data comprehensively captured all 
abortions among Ontario residents, as well as 
all subsequent hospital or health service events, 
even if such services were not provided by the 
same provider or facility that provided the initial 
care. Therefore, loss to follow-up was minimal 
since it involved only patients who had moved 
out of the province within 6 weeks after the abor-
tion or during the current pregnancy. However, 
since linkages across databases are possible only 
for residents who are eligible for provincial health 
insurance, we excluded the 397 abortions (0.1%) 
that were provided to nonresidents. Because of 
lags in availability of cause-of-death data, we 
could not report the incidence of abortion-related 
deaths. However, surveillance by the U.S. Centers 
for Disease Control and Prevention indicates that 
death is a very rare outcome (2 deaths among 
609,095 abortions in 2018).39 Although minimal 
data were missing for gestational trimester, we 
did not have data regarding specific gestational 
ages in weeks, which prevented an evaluation of 
changes to abortion timing within trimesters.
When mifepristone became available as a 
normally prescribed medication in Canada, the 
frequency of medical abortion rose substantially 
as compared with the frequency during the pe-
riod before mifepristone became available, even 
though the rate of abortion remained materially 
stable. The incidences of serious adverse events 
and complications remained materially unchanged, 
and uterine evacuation and ongoing pregnancy 
remained infrequent.
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